Rein Therapeutics opened lower at $0.60, compared with its previous close of $0.61. In the last trading session, the stock traded between $0.55 and $0.60. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Rein Therapeutics is now worth
$ 28.96
Resulting in a loss of
$ 71.04 (71.04%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.05 (-7.76%)
Day High
$0.60
Day Low
$0.55
Day Open
$0.60
Prev Close
$0.61
Volume
3,47,177
1W Return
-15.43%
1M Return
-28.15%
3M Return
-31.75%
6M Return
-51.39%
1Y Return
-62.48%
Fundamentals
Market Cap ($ Mn)
48
PE Ratio
-
PB Ratio
6.41
PEG Ratio
-
ROE
-
ROCE
-113.00%
EPS (TTM)
$-0.07
Investment Returns
1 Week
-15.43%
1 Month
-28.15%
3 Months
-31.75%
6 Months
-51.39%
9 Months
-52.63%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
4Sep
Rein Therapeutics to present LTI-03 IPF data at ERS 2026
Rein Therapeutics to present late-breaking poster on LTI-03 at ERS 2026 Congress. Study evaluates inhaled peptide therapy for idiopathic pulmonary fibrosis. RENEW Phase 2 trial enrolling approximately 120 patients across five countries. Primary efficacy endpoint is change from baseline in forced vital capacity. LTI-03 holds Orphan Drug and Fast Track designations in the U.S.
2mo ago
14Aug
Rein Therapeutics Q2 EPS $(0.10) beats $(0.17) estimate
Rein Therapeutics (NASDAQ: RNTX) delivered a better-than-expected Q2 2026 financial performance, reporting an EPS of $(0.10) against a consensus estimate of $(0.17). This marks a 64.29% year-over-year improvement in per-share losses compared to $(0.28) in Q2 2025. The company also secured $57.5 million through an oversubscribed public offering, providing sufficient liquidity to fund operations and its Phase 2 IPF trial into early 2028.
3mo ago
21Jul
Maxim Group initiates coverage on Rein Therapeutics with Buy rating, $4 target
Maxim Group analyst Jason McCarthy has initiated coverage on Rein Therapeutics with a Buy rating and announced a price target of $4.
